Spero Therapeutics Shares Fall Despite $105M Royalty Financing Deal with KKR

Shares of Spero Therapeutics fell sharply in pre-market trading Tuesday after the biopharmaceutical company announced a $105 million royalty financing agreement with an affiliate of KKR. The deal provides Spero with non-dilutive capital based on future sales of its recently approved antibiotic, Utebzi, to fund its immunology pipeline.

Details of the Financing Agreement

Spero Therapeutics has entered into a licensing agreement with Healthcare Royalty (HCRx), a business of global investment firm KKR. The deal monetizes a portion of the future revenue stream from Spero's antibiotic, Utebzi, also known as tebipenem pivoxil.

Under the terms of the agreement, HCRx will provide Spero with $105 million at closing. In exchange, HCRx will receive the rights to milestone and royalty payments Spero is entitled to from its commercial partner, GSK.

• HCRx will receive quarterly principal and interest payments from the GSK revenue stream until the loan balance is repaid.
• After the balance is repaid, Spero will retain 35% of all subsequent payments from GSK related to Utebzi sales.

Strategic Rationale and Market Reaction

Ad

Despite securing significant funding, Spero's shares traded approximately 12% lower in pre-market hours following the news. Such investor reactions can sometimes reflect concerns over the long-term value given up in royalty financing deals, even though they avoid shareholder dilution.

Spero stated the funds will primarily support the development of its lead immunology candidate, SP001, which is currently in Phase 2 trials. CEO Esther Rajavelu noted that the "transaction further strengthens our balance sheet and provides non-dilutive capital as we embark on an immunology-focused strategy." As a result of the financing, Spero has extended its cash runway guidance into the second half of 2029.

Context on Utebzi

The financing is tied to Utebzi, which received U.S. Food and Drug Administration (FDA) approval last month for the treatment of complicated urinary tract infections. Spero has granted an exclusive license to pharmaceutical giant GSK to develop and commercialize the drug in all territories except for certain Asian markets.

The company also disclosed a concurrent exclusive license agreement with Innovent Biologics for the SP001 asset, which the new capital is intended to support.